Iovance Biotherapeutics Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas

Iovance Biotherapeutics has reported positive early data from a pilot clinical trial of its lifileucel TIL cell therapy in advanced sarcomas, with a 50% objective response rate in the first six evaluable patients. The therapy showed a significant unmet medical need for aggressive cancers affecting over 8,000 patients annually across the US and Europe. Iovance plans to launch a single-arm registrational trial for second-line advanced UPS and DDLPS in Q2 2026.